CARASENT ASA NK 1332
Carasent ASA provides cloud based electronic health record solutions to the health care industry in Sweden, Norway, and internationally. The company offers Webdoc, a cloud-based EHR system; Metodika EPM, a solution designed for mid-to-large-sized organizations; Medrave M4 to give healthcare staff and managers an overview and clear picture of the patient group being treated; Health Profile Institu… Read more
CARASENT ASA NK 1332 (C34) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CARASENT ASA NK 1332 (C34) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CARASENT ASA NK 1332 - Net Assets Trend (None–None)
This chart illustrates how CARASENT ASA NK 1332's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CARASENT ASA NK 1332 (None–None)
The table below shows the annual net assets of CARASENT ASA NK 1332 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CARASENT ASA NK 1332's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CARASENT ASA NK 1332 Competitors by Market Cap
The table below lists competitors of CARASENT ASA NK 1332 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hap Seng Plantations Holdings Bhd
KLSE:5138
|
$108.46 Million |
|
Ca Toulouse 31 CCI
PA:CAT31
|
$108.47 Million |
|
Jiangsu Cowin Biotech Co. Ltd. A
SHG:688426
|
$108.49 Million |
|
Quess Corp Limited
NSE:QUESS
|
$108.52 Million |
|
Taisun Enterprise Co Ltd
TW:1218
|
$108.34 Million |
|
Doubleview Gold Corp
OTCQB:DBLVF
|
$108.33 Million |
|
V Zug Holding Ag
SW:VZUG
|
$108.32 Million |
|
Chengdu Lihang Technology Co.Ltd.
SHG:603261
|
$108.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CARASENT ASA NK 1332's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CARASENT ASA NK 1332's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CARASENT ASA NK 1332 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CARASENT ASA NK 1332's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $1,807,324,866
- Average return on equity (ROE) among peers: -12.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CARASENT ASA NK 1332 (C34) | €- | N/A | N/A | $108.35 Million |
| Schrödinger, Inc. (43Z) | $557.09 Million | -18.02% | 0.36x | $631.00 Million |
| DACHA STRATEGIC (7DC) | $40.24 Million | 0.65% | 0.08x | $81.97 Million |
| ABL Diagnostics Société anonyme (9BK0) | $6.77 Million | 0.80% | 1.20x | $371.65K |
| Zhejiang Taimei Medical Technology Co., Ltd. (A2V) | $1.04 Billion | -33.28% | 0.39x | $47.71 Million |
| ASCOM HLDG NA SF 0,50 (AH2N) | $80.00 Million | 16.88% | 1.43x | $190.62 Million |
| DocCheck AG (AJ91) | $18.14 Million | 3.32% | 0.15x | $18.00 Million |
| EM Systems Co. Ltd (EMO) | $17.69 Billion | 7.87% | 0.33x | $74.55 Million |
| Tempus AI (F3M) | $-1.38 Billion | 0.00% | 0.00x | $4.75 Billion |
| Pangenomic Health Inc. (LL3) | $2.24 Million | -118.14% | 0.15x | $4.82 Million |
| MeVis Medical Solutions AG (M3V) | $17.83 Million | 17.76% | 0.45x | $12.89 Million |